禁煙およびニコチン脱中毒製品の世界市場：産業分析・規模・シェア・成長・動向・予測 (2025-2032年)

主な洞察

• 禁煙およびニコチン脱中毒製品の市場規模 (2025年)：83億910万米ドル
• 市場規模の予測 (2032年)：163億9,930万米ドル
• 世界の市場成長率 (2025～2032年)：CAGR 10.2%

市場促進要因：

世界の禁煙およびニコチン脱中毒製品の市場は、心血管疾患、癌、呼吸器疾患など、たばこ使用に伴う健康被害への世界的な認識の高まりによって推進されています。公共の場での喫煙禁止、健康被害を訴えるグラフィック警告表示、たばこ製品への課税といった政府の規制は、消費者の禁煙意欲を強化しています。また、ニコチンパッチ、ガム、トローチ、バレニクリンやブプロピオンなどの処方薬といった多様な禁煙製品の入手が容易になったことで、個人に合わせた治療の選択肢が広がっています。さらに、行動変容を支援するデジタルヘルスプラットフォームやモバイルアプリの普及が、ユーザーの関与と治療の成功率を高める要因となっています。

市場機会：

たばこ規制プログラムへの政府投資の増加、禁煙治療に対する保険適用の拡大、依存症治療における個別化医療の進歩により、市場は有望な機会を示しています。加熱式たばこや、個別コーチングプラットフォーム、AIによる禁煙支援アプリ、薬理学的介入と行動療法を組み合わせた併用療法など、新たな製品フォーマットの登場により、治療のあり方が大きく変わろうとしています。製薬会社、デジタルヘルスプロバイダー、公衆衛生機関の間で戦略的パートナーシップを構築することで、特に支援が届きにくい地域におけるイノベーションとアクセス性の向上が期待されます。また、職場の健康促進プログラムや地域での啓発活動も、製品導入と認知向上のための新たなプラットフォームとして注目されています。

当レポートでは、世界の禁煙およびニコチン脱中毒製品の市場を調査し、市場の定義と概要、市場促進要因・抑制要因、各種動向、市場機会、課題、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

• 市場の範囲と定義
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
  • 課題
  • 主な動向
• マクロ経済要因
  • 世界のセクター別展望
  • 世界のGDP成長見通し
• COVID-19の影響分析
• 予測要因- 関連性と影響

第3章 付加価値洞察

• 製品採用分析
• 疾病疫学
• 技術の進歩
• 規制状況
• バリューチェーン分析
• 製品のUSP分析
• 主要な取引と合併
• PESTLE分析
• ポーターのファイブフォース分析

第4章 価格動向の分析

• 主なハイライト
• 製品価格に影響を与える主な要因
• 製品タイプ別の価格分析
• 地域価格と製品の嗜好

第5章 世界の禁煙およびニコチン脱中毒製品市場の展望

• 主なハイライト
• 市場規模の分析・予測
• 世界の水素トラック市場の展望：製品タイプ別
• 世界の水素トラック市場の展望：流通チャネル別
  • イントロダクション/主な調査結果
  • 過去の市場規模の分析
  • 現在の市場規模の分析・予測
  • 市場の魅力分析

第6章 世界の禁煙およびニコチン脱中毒製品市場の展望：地域別

• 主なハイライト
• 過去の市場規模の分析：地域別
• 現在の市場規模の分析・予測：地域別
  • 北米
  • 欧州
  • 東アジア
  • 南アジアとオセアニア
  • ラテンアメリカ
  • 中東・アフリカ
• 市場の魅力分析

第7章 北米の禁煙およびニコチン脱中毒製品市場の展望

第8章 欧州の禁煙およびニコチン脱中毒製品市場の展望

第9章 東アジアの禁煙およびニコチン脱中毒製品市場の展望

第10章 南アジアおよびオセアニアの禁煙およびニコチン脱中毒製品市場の展望

第11章 ラテンアメリカの禁煙およびニコチン脱中毒製品市場の展望

第12章 中東・アフリカの禁煙およびニコチン脱中毒製品市場の展望

第13章 競合情勢

• 市場シェア分析
• 市場構造
• 企業プロファイル (詳細- 概要、財務、戦略、最近の動向)
  • Cipla
  • Kenvue
  • Pfizer Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Aflofarm
  • Fertin Pharma A/S
  • Sopharma AD
  • Perrigo Company plc,
  • GSK Plc
  • Rusan Pharma.
  • British American Tobacco
  • Sun Pharmaceutical Industries Ltd.
  • GLENMARK PHARMACEUTICALS LTD.
  • ITC Limited
  • ZENIUS INDIA.
  • Piramal Pharma Limited
  • Swisher
  • LUCY GOODS
  • Mosaic Wellness PVT LTD.
  • Saisir Global Technologies Pvt Ltd
  • Lupin
  • その他

第14章 付録

Persistence Market Research has recently released a comprehensive report on the worldwide market for smoking cessation and nicotine de-addiction products. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global smoking cessation and nicotine de-addiction products market from 2025 to 2032.

Key Insights:

• Smoking Cessation and Nicotine De-Addiction Products Market Size (2025E): USD 8,309.1 Million
• Projected Market Value (2032F): USD 16,399.3 Million
• Global Market Growth Rate (CAGR 2025 to 2032): 10.2%

Smoking Cessation and Nicotine De-Addiction Products Market - Report Scope:

Smoking cessation and nicotine de-addiction products play a vital role in aiding individuals to overcome nicotine dependence, a major contributor to preventable diseases and premature mortality. These products, which include nicotine replacement therapies (NRTs), non-nicotine medications, e-cigarettes, and behavioral support tools, are used in medical settings, rehabilitation centers, and self-help programs to support tobacco users in quitting. The market serves a broad spectrum of users seeking structured de-addiction methods and is driven by growing awareness of smoking-related health risks, public health campaigns, and the implementation of strict tobacco control regulations.

Market Growth Drivers:

The global smoking cessation and nicotine de-addiction products market is driven by heightened global awareness of the health hazards associated with tobacco use, including cardiovascular disease, cancer, and respiratory conditions. Government regulations, such as bans on smoking in public spaces, graphic health warnings, and taxation on tobacco products, have bolstered consumer motivation to quit. The increasing availability of diverse cessation products-such as transdermal patches, nicotine gums, lozenges, and prescription medications like varenicline and bupropion-has expanded treatment options for individuals. Moreover, the rise of digital health platforms and mobile apps supporting behavior change enhances user engagement and therapy success rates.

Market Restraints:

Despite significant demand, the smoking cessation market faces barriers such as limited awareness of effective treatments in low- and middle-income countries, high costs associated with branded therapies, and social stigmas around seeking addiction treatment. Additionally, concerns regarding the safety and long-term effects of alternatives like e-cigarettes and vaping products have prompted regulatory scrutiny, leading to temporary bans or strict controls in several regions. The presence of unregulated products and misinformation about their efficacy or risks can further deter individuals from adopting evidence-based solutions, restricting overall market growth.

Market Opportunities:

The market presents promising opportunities due to increasing government investments in tobacco control programs, growing insurance coverage for cessation therapies, and advancements in personalized medicine for addiction treatment. Emerging product formats such as heat-not-burn devices, personalized coaching platforms, AI-driven quitting apps, and combination therapies integrating pharmacological and behavioral interventions are expected to transform the treatment landscape. Strategic partnerships between pharmaceutical companies, digital health providers, and public health institutions can also foster innovation and accessibility, especially in underserved regions. Additionally, workplace wellness programs and community outreach initiatives offer new platforms for product adoption and awareness.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the smoking cessation and nicotine de-addiction products market globally?
• Which product types and therapies are showing the highest adoption across regions?
• How are digital technologies and regulatory policies shaping the market landscape?
• Who are the leading companies in this market and what are their strategic growth initiatives?
• What are the future prospects and emerging trends in smoking cessation and nicotine de-addiction treatment?

Competitive Intelligence and Business Strategy:

Leading players in the global smoking cessation and nicotine de-addiction products market, including Mosaic Wellness PVT LTD., Aflofarm, Pfizer Inc., and Perrigo Company plc, are investing in research and development to improve product efficacy and user experience. These companies are expanding their product portfolios to include innovative delivery systems such as quick-dissolve strips and inhalers. Strategic mergers, acquisitions, and licensing agreements are being pursued to gain competitive advantages in regional markets. Moreover, partnerships with government agencies and health organizations support the delivery of cessation aids through subsidized or public health channels. Emphasis on digital integration, such as app-based therapy guidance and remote monitoring, is further transforming how cessation programs are delivered globally.

Key Companies Profiled:

• Cipla
• Kenvue
• Pfizer Inc.
• Dr. Reddy's Laboratories Ltd.
• Aflofarm
• Fertin Pharma A/S
• Sopharma AD
• Perrigo Company plc,
• GSK Plc
• Rusan Pharma.
• British American Tobacco
• Sun Pharmaceutical Industries Ltd.
• GLENMARK PHARMACEUTICALS LTD.
• ITC Limited
• ZENIUS INDIA.
• Piramal Pharma Limited
• Swisher
• LUCY GOODS
• Mosaic Wellness PVT LTD.
• Saisir Global Technologies Pvt Ltd
• Lupin

Market Segmentation

By Product Type

• Nicotine Replacement Therapy
• Lozenges
• Gums
• Sprays
• Inhalers
• patches
• Drug Therapy
• Varenicline-based Drugs
• Bupropion-based Drugs
• Cytisine-based Drugs

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Supermarkets/Hypermarkets

By Region

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Smoking Cessation and Nicotine De-Addiction Products Market Snapshot, 2025-2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Product Adoption Analysis
• 3.2. Disease Epidemiology
• 3.3. Technological Advancement
• 3.4. Regulatory Landscape
• 3.5. Value Chain Analysis
• 3.6. Product USP Analysis
• 3.7. Key Deals and Mergers
• 3.8. PESTLE Analysis
• 3.9. Porter's Five Force Analysis

4. Price Trend Analysis, 2019-2032

• 4.1. Key Highlights
• 4.2. Key Factors Impacting Product Prices
• 4.3. Pricing Analysis by Product Type
• 4.4. Regional Prices and Product Preferences

5. Global Smoking Cessation and Nicotine De-Addiction Products Market Outlook:

• 5.1. Key Highlights
  • 5.1.1. Market Size (US$ Mn) and Y-o-Y Growth
  • 5.1.2. Absolute $ Opportunity
• 5.2. Market Size (US$ Mn) Analysis and Forecast
  • 5.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
  • 5.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
• 5.3. Global Smoking Cessation and Nicotine De-Addiction Products Market Outlook: Product Type
  • 5.3.1. Introduction / Key Findings
  • 5.3.2. Historical Market Size (US$ Mn), By Product Type, 2019-2024
  • 5.3.3. Current Market Size (US$ Mn) and Forecast, By Product Type, 2025-2032
    • 5.3.3.1. Nicotine Replacement Therapy
      • 5.3.3.1.1. Lozenges
      • 5.3.3.1.2. Gums
      • 5.3.3.1.3. Sprays
      • 5.3.3.1.4. Inhalers
      • 5.3.3.1.5. Patches
    • 5.3.3.2. Drug Therapy
      • 5.3.3.2.1. Varenicline-based Drugs
      • 5.3.3.2.2. Bupropion-based Drugs
      • 5.3.3.2.3. Cytisine-based Drugs
  • 5.3.4. Market Attractiveness Analysis: Product Type
• 5.4. Global Smoking Cessation and Nicotine De-Addiction Products Market Outlook: Distribution Channel
  • 5.4.1. Introduction / Key Findings
  • 5.4.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019-2024
  • 5.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 5.4.3.1. Hospital Pharmacies
    • 5.4.3.2. Retail Pharmacies
    • 5.4.3.3. Online Pharmacies
    • 5.4.3.4. Supermarkets/Hypermarkets
  • 5.4.4. Market Attractiveness Analysis: Distribution Channel

6. Global Smoking Cessation and Nicotine De-Addiction Products Market Outlook: Region

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Mn), By Region, 2019-2024
• 6.3. Current Market Size (US$ Mn) and Forecast, By Region, 2025-2032
  • 6.3.1. North America
  • 6.3.2. Europe
  • 6.3.3. East Asia
  • 6.3.4. South Asia and Oceania
  • 6.3.5. Latin America
  • 6.3.6. Middle East & Africa
• 6.4. Market Attractiveness Analysis: Region

7. North America Smoking Cessation and Nicotine De-Addiction Products Market Outlook:

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Mn), By Market, 2019-2024
  • 7.2.1. By Country
  • 7.2.2. By Product Type
  • 7.2.3. By Distribution Channel
• 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 7.3.1. U.S.
  • 7.3.2. Canada
• 7.4. Current Market Size (US$ Mn) and Forecast, By Product Type, 2025-2032
  • 7.4.1. Nicotine Replacement Therapy
    • 7.4.1.1. Lozenges
    • 7.4.1.2. Gums
    • 7.4.1.3. Sprays
    • 7.4.1.4. Inhalers
    • 7.4.1.5. patches
  • 7.4.2. Drug Therapy
    • 7.4.2.1. Varenicline-based Drugs
    • 7.4.2.2. Bupropion-based Drugs
    • 7.4.2.3. Cytisine-based Drugs
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 7.5.1. Hospital Pharmacies
  • 7.5.2. Retail Pharmacies
  • 7.5.3. Online Pharmacies
  • 7.5.4. Supermarkets/Hypermarkets
• 7.6. Market Attractiveness Analysis

8. Europe Smoking Cessation and Nicotine De-Addiction Products Market Outlook:

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Mn), By Market, 2019-2024
  • 8.2.1. By Country
  • 8.2.2. By Product Type
  • 8.2.3. By Distribution Channel
• 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 8.3.1. Germany
  • 8.3.2. France
  • 8.3.3. U.K.
  • 8.3.4. Italy
  • 8.3.5. Spain
  • 8.3.6. Russia
  • 8.3.7. Turkey
  • 8.3.8. Rest of Europe
• 8.4. Current Market Size (US$ Mn) and Forecast, By Product Type, 2025-2032
  • 8.4.1. Nicotine Replacement Therapy
    • 8.4.1.1. Lozenges
    • 8.4.1.2. Gums
    • 8.4.1.3. Sprays
    • 8.4.1.4. Inhalers
    • 8.4.1.5. patches
  • 8.4.2. Drug Therapy
    • 8.4.2.1. Varenicline-based Drugs
    • 8.4.2.2. Bupropion-based Drugs
    • 8.4.2.3. Cytisine-based Drugs
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 8.5.1. Hospital Pharmacies
  • 8.5.2. Retail Pharmacies
  • 8.5.3. Online Pharmacies
  • 8.5.4. Supermarkets/Hypermarkets
• 8.6. Market Attractiveness Analysis

9. East Asia Smoking Cessation and Nicotine De-Addiction Products Market Outlook:

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Mn), By Market, 2019-2024
  • 9.2.1. By Country
  • 9.2.2. By Product Type
  • 9.2.3. By Distribution Channel
• 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 9.3.1. China
  • 9.3.2. Japan
  • 9.3.3. South Korea
• 9.4. Current Market Size (US$ Mn) and Forecast, By Product Type, 2025-2032
  • 9.4.1. Nicotine Replacement Therapy
    • 9.4.1.1. Lozenges
    • 9.4.1.2. Gums
    • 9.4.1.3. Sprays
    • 9.4.1.4. Inhalers
    • 9.4.1.5. patches
  • 9.4.2. Drug Therapy
    • 9.4.2.1. Varenicline-based Drugs
    • 9.4.2.2. Bupropion-based Drugs
    • 9.4.2.3. Cytisine-based Drugs
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 9.5.1. Hospital Pharmacies
  • 9.5.2. Retail Pharmacies
  • 9.5.3. Online Pharmacies
  • 9.5.4. Supermarkets/Hypermarkets
• 9.6. Market Attractiveness Analysis

10. South Asia & Oceania Smoking Cessation and Nicotine De-Addiction Products Market Outlook:

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Mn), By Market, 2019-2024
  • 10.2.1. By Country
  • 10.2.2. By Product Type
  • 10.2.3. By Distribution Channel
• 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 10.3.1. India
  • 10.3.2. Southeast Asia
  • 10.3.3. ANZ
  • 10.3.4. Rest of South Asia & Oceania
• 10.4. Current Market Size (US$ Mn) and Forecast, By Product Type, 2025-2032
  • 10.4.1. Nicotine Replacement Therapy
    • 10.4.1.1. Lozenges
    • 10.4.1.2. Gums
    • 10.4.1.3. Sprays
    • 10.4.1.4. Inhalers
    • 10.4.1.5. patches
  • 10.4.2. Drug Therapy
    • 10.4.2.1. Varenicline-based Drugs
    • 10.4.2.2. Bupropion-based Drugs
    • 10.4.2.3. Cytisine-based Drugs
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 10.5.1. Hospital Pharmacies
  • 10.5.2. Retail Pharmacies
  • 10.5.3. Online Pharmacies
  • 10.5.4. Supermarkets/Hypermarkets
• 10.6. Market Attractiveness Analysis

11. Latin America Smoking Cessation and Nicotine De-Addiction Products Market Outlook:

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Mn), By Market, 2019-2024
  • 11.2.1. By Country
  • 11.2.2. By Product Type
  • 11.2.3. By Distribution Channel
• 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 11.3.1. Brazil
  • 11.3.2. Mexico
  • 11.3.3. Rest of Latin America
• 11.4. Current Market Size (US$ Mn) and Forecast, By Product Type, 2025-2032
  • 11.4.1. Nicotine Replacement Therapy
    • 11.4.1.1. Lozenges
    • 11.4.1.2. Gums
    • 11.4.1.3. Sprays
    • 11.4.1.4. Inhalers
    • 11.4.1.5. patches
  • 11.4.2. Drug Therapy
    • 11.4.2.1. Varenicline-based Drugs
    • 11.4.2.2. Bupropion-based Drugs
    • 11.4.2.3. Cytisine-based Drugs
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 11.5.1. Hospital Pharmacies
  • 11.5.2. Retail Pharmacies
  • 11.5.3. Online Pharmacies
  • 11.5.4. Supermarkets/Hypermarkets
• 11.6. Market Attractiveness Analysis

12. Middle East & Africa Smoking Cessation and Nicotine De-Addiction Products Market Outlook:

• 12.1. Key Highlights
• 12.2. Historical Market Size (US$ Mn), By Market, 2019-2024
  • 12.2.1. By Country
  • 12.2.2. By Product Type
  • 12.2.3. By Distribution Channel
• 12.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 12.3.1. GCC Countries
  • 12.3.2. Egypt
  • 12.3.3. South Africa
  • 12.3.4. Northern Africa
  • 12.3.5. Rest of Middle East & Africa
• 12.4. Current Market Size (US$ Mn) and Forecast, By Product Type, 2025-2032
  • 12.4.1. Nicotine Replacement Therapy
    • 12.4.1.1. Lozenges
    • 12.4.1.2. Gums
    • 12.4.1.3. Sprays
    • 12.4.1.4. Inhalers
    • 12.4.1.5. patches
  • 12.4.2. Drug Therapy
    • 12.4.2.1. Varenicline-based Drugs
    • 12.4.2.2. Bupropion-based Drugs
    • 12.4.2.3. Cytisine-based Drugs
• 12.5. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
  • 12.5.1. Hospital Pharmacies
  • 12.5.2. Retail Pharmacies
  • 12.5.3. Online Pharmacies
  • 12.5.4. Supermarkets/Hypermarkets
• 12.6. Market Attractiveness Analysis

13. Competition Landscape

• 13.1. Market Share Analysis, 2025
• 13.2. Market Structure
  • 13.2.1. Competition Intensity Mapping by Market
  • 13.2.2. Competition Dashboard
• 13.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 13.3.1. Cipla
    • 13.3.1.1. Overview
    • 13.3.1.2. Segments and Product
    • 13.3.1.3. Key Financials
    • 13.3.1.4. Market Developments
    • 13.3.1.5. Market Strategy
  • 13.3.2. Kenvue
  • 13.3.3. Pfizer Inc.
  • 13.3.4. Dr. Reddy's Laboratories Ltd.
  • 13.3.5. Aflofarm
  • 13.3.6. Fertin Pharma A/S
  • 13.3.7. Sopharma AD
  • 13.3.8. Perrigo Company plc,
  • 13.3.9. GSK Plc
  • 13.3.10. Rusan Pharma.
  • 13.3.11. British American Tobacco
  • 13.3.12. Sun Pharmaceutical Industries Ltd.
  • 13.3.13. GLENMARK PHARMACEUTICALS LTD.
  • 13.3.14. ITC Limited
  • 13.3.15. ZENIUS INDIA.
  • 13.3.16. Piramal Pharma Limited
  • 13.3.17. Swisher
  • 13.3.18. LUCY GOODS
  • 13.3.19. Mosaic Wellness PVT LTD.
  • 13.3.20. Saisir Global Technologies Pvt Ltd
  • 13.3.21. Lupin
  • 13.3.22. Others

14. Appendix

• 14.1. Research Methodology
• 14.2. Research Assumptions
• 14.3. Acronyms and Abbreviations